Abstract
Leishmaniasis affects approximately 2 million people each year throughout the world. This high incidence is due in part to the lack of an efficacious vaccine. We present evidence that the recombinant leishmanial antigens LmSTI1 and TSA, which we identified and characterized previously, induce excellent protection in both murine and nonhuman primate (rhesus monkey) models of human cutaneous leishmaniasis. The remarkable protection induced by LmSTI1 and TSA in an animal model that is evolutionarily close to humans qualifies this antigen combination as a promising candidate subunit vaccine against human leishmaniasis.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antibodies, Protozoan / blood
-
Antigens, Protozoan / genetics
-
Antigens, Protozoan / immunology*
-
Disease Models, Animal*
-
Heat-Shock Proteins / genetics
-
Heat-Shock Proteins / immunology
-
Humans
-
Leishmania major / immunology*
-
Leishmaniasis, Cutaneous / prevention & control*
-
Macaca mulatta
-
Mice
-
Mice, Inbred BALB C
-
Neoplasm Proteins*
-
Peroxidases / genetics
-
Peroxidases / immunology
-
Peroxiredoxin III
-
Peroxiredoxins
-
Protozoan Proteins*
-
Protozoan Vaccines / genetics
-
Protozoan Vaccines / immunology*
-
Recombinant Proteins / genetics
-
Recombinant Proteins / immunology
-
T-Lymphocytes / immunology
-
Vaccination
Substances
-
Antibodies, Protozoan
-
Antigens, Protozoan
-
Heat-Shock Proteins
-
Neoplasm Proteins
-
Prdx3 protein, mouse
-
Protozoan Proteins
-
Protozoan Vaccines
-
Recombinant Proteins
-
stress-inducible protein 1, Leishmania major
-
Peroxidases
-
PRDX3 protein, human
-
Peroxiredoxin III
-
Peroxiredoxins